Chapter 5

UVA-1 cold light treatment of SLE: a double blind, placebo controlled crossover trial

M.C.A. Polderman, T.W.J. Huizinga, S. Le Cessie, S. Pavel

Ann Rheum Dis 2001;60:112-115
Abstract

Objective: Treatment of patients with systemic lupus erythematosus (SLE) often implies strong drugs with possibly serious side effects. Thus, there is a need for new immunosuppressive treatments. Long wave ultraviolet A (UVA-1) cold light therapy is an anti-inflammatory, immunomodulatory treatment with a possible systemic effect and few side effects. In the current study low dose UVA-1 cold light treatment was tested to determine whether it reduces disease activity in SLE.

Methods: Eleven patients with SLE were treated with UVA-1 cold light treatment and a placebo light treatment in a double blind, placebo controlled, crossover study. In two consecutive 12 week periods the patients were treated in the first three weeks with UVA-1 and placebo treatment or vice versa. The primary variables were the SLE Disease Activity Index (SLEDAI) and SLE Activity Measure (SLAM).

Results: The mean SLAM and SLEDAI showed a significant decrease of 30.4% (p=0.0005) and 37.9% (p=0.016) respectively after three weeks of UVA-1, and a non-significant decline of 9.3% (p=0.43) and 12.2% (p=0.54) respectively after three weeks of placebo treatment. In this small trial the difference in reduction of the disease activity indices during UVA-1 compared with during placebo treatment failed to reach the conventional border of significance (p=0.07). The total score of quality of life measure MOS SF36 did not improve significantly, but the subscore for vitality did improve.

Conclusion: Low dose UVA-1 cold light treatment was strongly suggestive of lowering disease activity in this double blind, placebo controlled study, and no side effects occurred.
Introduction

Current treatment of systemic lupus erythematosus (SLE) comprises non-steroidal anti-inflammatory drugs (NSAIDs), antimalarial drugs, prednisone, azathioprine, cyclophosphamide, chlorambucil, and methotrexate. These are drugs with potential side effects. Thus there is a need for alternative immunosuppressive treatments. Long wave ultraviolet A (UVA-1) cold light therapy is an immunosuppressive treatment\textsuperscript{1,2} with proven efficacy in patients with atopic dermatitis.\textsuperscript{3} The main short term side effects are a little sunburn and slight xerosis cutis. Although animal experiments suggest that UVA-1 is less carcinogenic than UVA-2 and UVB,\textsuperscript{4} the severity of long term side effects, like carcinogenicity and aging, is not yet clear. Compared with UVB (280-320 nm) and UVA-2 (320-340 nm), UVA-1 (340-400 nm) penetrates deeper into the skin, as far as the deeper layers of the dermis. Because of that deeper penetration the immunosuppressive and anti-inflammatory effects of UVA-1 are thought to be moderately systemic.

For a long time exposure to sunlight has been associated with exacerbation of SLE.\textsuperscript{5,6} Approximately 45\% of patients with SLE are known to have photosensitivity.\textsuperscript{7} After exposure to sunlight patients show persistent erythema, erythematous papules or papulovesicles. Mainly UVB and, to a lesser extend UVA, are held responsible for the signs of photosensitivity occurring.\textsuperscript{8} Accordingly, the first reports on the beneficial effects of long wave UVA-1 in patients with SLE were unexpected.

In 1987 McGrath Jr \textit{et al} described the favourable effect of UVA on SLE activity. Survival was prolonged only in irradiated mice in the New Zealand black/New Zealand white mouse model of SLE. Irradiated mice, compared with those not irradiated, had decreased anti-dsDNA levels and decreased spleen size at necropsy. Irradiation comprised wavelengths
predominantly in the UVA range (320-400 nm). Later, these authors also reported that low dose UVA-1 induced decreases of clinical disease activity, doses of systemic steroids, and autoantibodies in humans and improved disease activity scores during maintenance treatment when patients were irradiated twice a week for eight months after the initial three week treatment period. In 1993 Sonnichsen et al. published a case report about the successful treatment of a patient with subacute cutaneous lupus erythematosus with UVA-1.

As UVA-1 irradiation may be promising in the treatment of SLE and as studies to determine the efficacy of UVA-1 in the treatment of SLE have been carried out by one research group only, we treated 11 patients with SLE in a double blind, placebo controlled, crossover study to compare results and establish a basis for further clinical and laboratory investigation.

**Patients and methods**

**Patients**

Eleven patients with mild to moderate SLE were included in this prospective study (Table 1). Patients (one male, 10 female) were recruited from the SLE outpatients’ clinic of the rheumatology department. Their mean age was 38.1 years (range 18-56, median 35). Nine patients were white subjects, one was Surinam creole, and one was Indonesian. At entry their disease had a mean duration of 7.8 years (range 2-19, median 6). All patients fulfilled four or more American College of Rheumatology criteria for the diagnosis SLE and an SLE Disease Activity Index (SLEDAI) of at least four. Patients were not allowed to change their drugs two months before entry. During the study, changes in drugs (except for NSAIDs) could only be made by the rheumatologist.
Table 5.1. Patients’ characteristics

<table>
<thead>
<tr>
<th>No</th>
<th>Age</th>
<th>Sex</th>
<th>Skin colour</th>
<th>Disease (years)</th>
<th>SLEDAI at start study</th>
<th>SLAM at start study</th>
<th>SLEDAI during UVA-1</th>
<th>SLEDAI during placebo</th>
<th>SLAM during UVA-1</th>
<th>SLAM during placebo</th>
<th>Drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>35.0</td>
<td>F</td>
<td>White</td>
<td>6</td>
<td>17</td>
<td>9</td>
<td>-1</td>
<td>-0.5</td>
<td>-3</td>
<td>-2</td>
<td>Plaquenil 1x200 mg</td>
</tr>
<tr>
<td>2</td>
<td>29.2</td>
<td>F</td>
<td>White</td>
<td>7</td>
<td>12</td>
<td>12</td>
<td>-9</td>
<td>+2</td>
<td>-1</td>
<td>+1</td>
<td>Plaquenil 2x200 mg, diclofenac 2x75 mg</td>
</tr>
<tr>
<td>3</td>
<td>27.5</td>
<td>F</td>
<td>White</td>
<td>6</td>
<td>13</td>
<td>17</td>
<td>-4</td>
<td>-3</td>
<td>-6</td>
<td>-3</td>
<td>Ibuprofen 3x400 mg</td>
</tr>
<tr>
<td>4</td>
<td>48.6</td>
<td>F</td>
<td>Dark</td>
<td>3</td>
<td>12</td>
<td>15</td>
<td>-10</td>
<td>0</td>
<td>-2</td>
<td>-6</td>
<td>Plaquenil 1x200 mg, prednisone 1x10 mg, diclofenac 2x50 mg</td>
</tr>
<tr>
<td>5</td>
<td>30.9</td>
<td>F</td>
<td>White</td>
<td>8</td>
<td>16</td>
<td>13</td>
<td>-2</td>
<td>-4</td>
<td>-6</td>
<td>+8</td>
<td>Plaquenil 2x200 mg, prednisone 1x5 mg, naproxen 250 mg/week</td>
</tr>
<tr>
<td>6</td>
<td>18.4</td>
<td>F</td>
<td>White</td>
<td>2</td>
<td>7</td>
<td>12</td>
<td>+6</td>
<td>+1</td>
<td>-1</td>
<td>+2</td>
<td>Plaquenil 1x200 mg, prednisone 1x5 mg, ibuprofen 2x800 mg</td>
</tr>
<tr>
<td>7</td>
<td>54.8</td>
<td>F</td>
<td>Dark</td>
<td>5</td>
<td>26</td>
<td>15</td>
<td>-19</td>
<td>+6</td>
<td>-3</td>
<td>0</td>
<td>Prednisone 1x15 mg</td>
</tr>
<tr>
<td>8</td>
<td>34.9</td>
<td>F</td>
<td>White</td>
<td>19</td>
<td>14</td>
<td>16</td>
<td>-2</td>
<td>-2</td>
<td>-8</td>
<td>0</td>
<td>Plaquenil 1x200 mg</td>
</tr>
<tr>
<td>9</td>
<td>41.4</td>
<td>F</td>
<td>White</td>
<td>8</td>
<td>10</td>
<td>13</td>
<td>-4</td>
<td>-6</td>
<td>-7</td>
<td>-5</td>
<td>Prednisone 1x7 mg, naproxen 3x250 mg</td>
</tr>
<tr>
<td>10*</td>
<td>42.0</td>
<td>F</td>
<td>White</td>
<td>17</td>
<td>12</td>
<td>15</td>
<td>-9</td>
<td>0</td>
<td>-4</td>
<td>+1</td>
<td>Plaquenil 3x200 mg, prednisone 1x5 mg, ibuprofen 2x400 mg</td>
</tr>
<tr>
<td>11*</td>
<td>56.2</td>
<td>M</td>
<td>White</td>
<td>5</td>
<td>20</td>
<td>17</td>
<td>-7</td>
<td>-8</td>
<td>-4</td>
<td>-9</td>
<td>Arthrotec 1x75 mg</td>
</tr>
</tbody>
</table>

*Patients who received placebo treatment first.

†Decrease (-) and increase (+) of SLAM and SLEDAI score during UVA-1 and placebo treatment.
Irradiation equipment

For UVA-1 irradiation the Photomed 250 000 (Photomed Medizintechnik GmbH Vertrieb Deutschland, Gehrden, Germany) was used. It emits photons with wavelengths longer than 340 nm. The instrument is equipped with a filter system that eliminates all infrared radiation, which significantly reduces heat production and increases comfort for the patients. Owing to these filters, the ventilation system that provides the patient with a cool breeze, and the blue color of the light, Photomed UVA-1 treatment is also called UVA-1 cold light treatment.

The placebo treatment comprised TL light tubes that could be placed under the UVA-1 light tubes. In this way patients used the same cabin for both treatments. To match the blue colour of the UVA-1 treatment, blue plastic covered the frame with the TL tubes. Patients could recognise differences between the lamps but they did not know which was the supposedly effective treatment. During both treatments patients wore protective eyewear.

Treatment schedule

The study had a double blind, placebo controlled, crossover design. During two consecutive 12 week periods patients were treated in the first 3 weeks. The following 9 weeks served as a wash out period. Patients were randomly allocated to group A (n=9) or group B (n=2) by an independent person. Irradiation consisted of total body irradiation with 6 J/cm², five days a week for three weeks or an equivalent time of exposure (3 minutes, 20 seconds) to placebo light. Group A was treated with UVA-1 for the first three weeks and was crossed over to be treated with the placebo light treatment in the second treatment period. Group B was treated with both UVA-1 and placebo light treatment in reverse succession. Irradiation was carried out during the winter months to minimise concomitant exposure to natural sunlight. Variables were evaluated every three weeks by the doctor until nine weeks after the last three week
treatment period. Both the doctor and the patients were blinded to the treatment throughout the study.

Our primary measures were two systems for clinical assessment of SLE activity, the SLE Disease Activity Index (SLEDAI)\textsuperscript{13} and the SLE Activity Measure (SLAM).\textsuperscript{14} The SLEDAI consists of 19 items representing nine organ systems. Each item is rated as present or absent. The SLAM includes 24 clinical manifestations for nine organ systems and eight laboratory variables to evaluate organs that cannot otherwise be assessed. All items are scored as 0 to 2, or 0 to 3 according to their severity. Two 100 mm visual analogue scales (VAS) accompany the SLAM score to measure the patient’s and doctor’s subjective ratings of disease activity. We decided to use the SLEDAI score because it discriminates single disease activity states among subjects well and completion costs little time. We included the SLAM score because it detects a treatment effect more sensitively.\textsuperscript{14} Furthermore, drugs were monitored and the patients filled in a validated quality of life questionnaire, Medical Outcome Study 36-item short-form health survey (MOS SF36),\textsuperscript{15} at each control visit. This quality of life questionnaire was rated in total as well as in separate scores for different features of quality of life: physical, social, and mental functioning, pain, vitality, and change in state of health. Apart from evaluation of clinical variables, titres of antibodies to SSA, SSB, Sm and RNP were determined as well as antinuclear antibodies and anti-dsDNA. Furthermore, a complete blood count, an erythrocyte sedimentation rate (ESR), and urine analysis were done every three weeks.

\textit{Statistical methods}

McGrath found a 39\% decrease (=6 points, SD 4.295, p<0.005) of disease activity scores in 10 patients who were treated with UVA-1.\textsuperscript{11} To detect a decrease of six points when treated
with UVA-1 and 0 points when treated with placebo (SD 4.295) with a power of 80% (\(\alpha=0.05\), two sided tests) 11 patients were needed. A paired Wilcoxon test was used to determine changes in clinical and laboratory variables before and after UVA-1 and placebo irradiation and to determine significant differences (p<0.05) between improvement by UVA-1 and improvement by placebo treatment. All variables were evaluated for period and carry over effects.

**Results**

Of the 11 patients included in this study, none was lost to follow up. Clinical disease activity scores decreased more after three weeks of treatment with UVA-1 than after three weeks of placebo treatment. The mean SLAM showed a significant decrease of 30.4% (4.09 points, 95% confidence interval (CI) 2.49 to 5.69) after three weeks of UVA-1 by decreasing from 13.45 (=100%, SD (2.21)=16.43%) to 9.36 (=69.59%, SD (2.42)=17.99%) (p=0.0005) (Fig. 5.1). Although the mean SLAM showed a non-significant decline of 9.3% (1.18 points, 95% CI –1.89 to 4.26) from 12.73 (=100%, SD (3.35)=26.32%) to 11.55 (=90.73%, SD (3.56)=27.97%) (p=0.43) after three weeks of placebo treatment, the SLAM did not decrease significantly more after UVA-1 than after placebo treatment (mean -2.91, 95% CI -6.39 to 0.57, p=0.07). Similarly, the SLEDAI decreased by 37.9% (5.55 points, 95% CI 1.24 to 9.85) after UVA-1 treatment and 12.2% (1.32 points, 95% CI -1.29 to 3.93) after placebo treatment, that is, from 14.64 (=100%, SD 5.12=34.97%) to 9.09 (=62.09%, SD 4.78=32.65%) after UVA-1 (p= 0.016) and from 10.82 (=100%, SD 5.78=53.41%) to 9.50 (=87.8%, SD 3.93=36.32%) after placebo treatment (p=0.54) (Fig. 5.1.). Again, the difference between decrease of SLEDAI after UVA-1 and after placebo was not significant (mean -4.23,
Figure 5.1. SLAM and SLEDAI showed statistically significant improvement during UVA-1. Improvement of these variables during placebo treatment was not statistically significant.

95% CI-10.11 to 1.65, p=0.07). Until six weeks after UVA-1 the decrease of SLAM and SLEDAI was significant compared with the SLAM and SLEDAI scores before treatment. Thus, the clinical effect of UVA-1 lasted for six to nine weeks. SLAM and SLEDAI scores did not show significant decreases immediately after, three, six, or nine weeks after placebo treatment.

The nine organ systems of the SLAM score were also evaluated separately. The score of integument (oral ulcers + cutaneous rash + vasculitis + alopecia) and the cardiovascular score (Raynaud + hypertension + carditis) showed significant improvement after UVA-1 cold light treatment in comparison with placebo treatment (p=0.04 and 0.03 respectively). These results were mainly due to improvement of rash (p=0.08) and Raynaud’s phenomenon (p=0.06). Improvements in the other seven organ systems were not statistically significant.

Also, the MOS SF36 subscore for vitality improved more after UVA-1 (-15.91 points, from 33.64 to 49.55, 95% CI -29.58 to -2.24) than after placebo treatment (2.27 points, from 47.27
to 45.00, 95% CI -8.60 to 13.14) (p=0.03). Changes in the MOS SF36 total score and in the remaining subscores after UVA-1 were not statistically significantly different from changes in these scores after placebo treatment.

Four patients were anti-SSA positive. In these four patients a mean decrease of anti-SSA antibody titres of 2.75 U/ml was found after UVA-1 (from 87 to 84.25, 95% CI 3.25 x 10^{-2} to 5.47) and a very small mean increase of 0.25 U/ml after placebo treatment (from 83 to 83.25, 95% CI -3.26 to 2.76) was seen; the difference was not significant (p=0.06), however. Seroconversion from a positive to a negative anti-SSA status did not occur. Anti-dsDNA antibody status did not differ significantly throughout the study. Changes in the doctor’s and the patient’s VAS and changes in the complete blood count, the ESR, and the urine analysis after UVA-1 were not different from after placebo treatment. No changes in drugs were made. None of the evaluated variables showed a period or carry over effect. Despite the fact that five of the 11 patients were known occasionally to be photosensitive, no signs of photosensitivity or other side effects occurred during UVA-1 or placebo treatment.

**Discussion**

Improvement of SLAM and SLEDAI during UVA-1 treatment was significant, whereas improvement of both scores during placebo was not. Although the small number of patients resulted in a p value of 0.07, we suggest that the better improvement of the SLAM and SLEDAI during UVA-1 compared with during placebo treatment has obvious clinical importance. We make this suggestion especially because UVA-1 has few short term side effects and certainly the side effect profile is better than that of most of the alternative treatments for SLE. Apart from improvement of SLAM and SLEDAI scores, which contain
both objective and subjective variables, objective serological monitoring of disease activity by evaluating titres of anti-SSA showed an obvious trend of improvement during UVA-1 treatment in the four anti-SSA positive patients included.

The statistically significant improvement of the integument and cardiovascular subscores of the SLAM and of the vitality subscore of the MOS SF36 quality of life index should be interpreted with some caution. It should be kept in mind that testing of subscores increases the risk of statistical significance by chance. One could correct by Bonferroni correction, though this method is considered to be conservative.

In a double blind, placebo controlled, crossover design McGrath et al. treated 26 patients with SLE with less favourable results. After UVA-1 treatment, group A showed a significant 1.7 point decrease of the SLAM from 8.4 (2.9) to 6.7 (1.9) (p<0.05). Decrease of the SLAM in group B after UVA-1 was not statistically significant. The lack of wash out periods in their study risked carry over effects. Furthermore, the authors did not evaluate placebo effects by comparing the changes in SLAM after UVA-1 with the changes in SLAM after placebo treatment. In an uncontrolled study McGrath treated 10 patients with 6 J/cm² UVA-1 (five times a week for three weeks). The treatment resulted in improvement of various clinical measures. However, these variables were not combined in a commonly used disease activity scoring system and were consequently not easily comparable with our results. Furthermore, a different type of UVA-1 lamp was used.

The working mechanisms of UVA-1 are largely unknown. In the treatment of atopic dermatitis UVA-1 light is used in much higher doses. Apoptosis of certain T cell populations, resulting from singlet oxygen generation, is believed to play a part in this therapeutic effect. Owing to the apparent risk of photosensitivity in patients with SLE, we used a very low dose of UVA-1. No signs of photosensitivity occurred in any of our patients. Symptoms of
photosensitivity are reported to occur in patients with SLE when irradiated with UVA doses higher than 20 J/cm\(^2\),\(^8\) and thus a UVA-1 dose higher than 6 J/cm\(^2\) might result in a better outcome. Also, it is not known how long the clinical effect of UVA-1 in patients with SLE lasts once the treatment is stopped. In our trial the effect lasted for six to nine weeks. A maintenance treatment of one or two irradiations a week might possibly prolong clinical effectivity.

The working mechanism of UVA-1, the effect of a higher dose of UVA-1, and the effect of maintenance UVA-1 treatment in patients with SLE are currently under investigation.

**Acknowledgements**

We thank the Dutch League against Rheumatism for financing this research project and Mrs. M. Kompas for analysis of autoantibody titres.
References


